Astrana Health, Inc. (NASDAQ:ASTH) Receives $65.60 Average Price Target from Brokerages

Astrana Health, Inc. (NASDAQ:ASTH) has received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $56.83.

Several research firms recently weighed in on ASTH. Robert W. Baird decreased their price objective on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday. Truist Financial dropped their price target on Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, January 13th. Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. Stifel Nicolaus lowered their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. Finally, Bank of America decreased their target price on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday.

Astrana Health Trading Up 0.1 %

Shares of ASTH stock opened at $27.21 on Friday. The stock’s 50-day moving average price is $34.44 and its 200-day moving average price is $44.05. Astrana Health has a 12-month low of $23.12 and a 12-month high of $63.20. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of 20.93, a price-to-earnings-growth ratio of 1.37 and a beta of 1.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). The company had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Equities research analysts predict that Astrana Health will post 1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC purchased a new position in Astrana Health during the 3rd quarter valued at about $35,000. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Astrana Health during the fourth quarter valued at $40,000. Quarry LP increased its position in Astrana Health by 35.5% during the 4th quarter. Quarry LP now owns 1,799 shares of the company’s stock worth $57,000 after purchasing an additional 471 shares in the last quarter. KBC Group NV purchased a new position in Astrana Health in the 3rd quarter valued at about $70,000. Finally, Quest Partners LLC acquired a new stake in shares of Astrana Health during the 3rd quarter worth about $133,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.